Investigator Calls for Early Listing of Zolgensma in Japan

Kayoko Saito, Director, Institute of Clinical Genomics, Tokyo Women’s Medical University The Japanese government should get Novartis’ gene therapy Zolgensma (onasemnogene abeparvovec) listed as soon as possible as the clock is ticking for patients with spinal muscular atrophy (SMA), Kayoko...read more